PBFT 02
Alternative Names: AAV-Granulin Gene Therapy; AAV1-GRN vector; PBFT-02Latest Information Update: 17 Mar 2025
At a glance
- Originator University of Pennsylvania
- Developer Passage Bio
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference; Progranulin protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Frontotemporal dementia
- Preclinical Amyotrophic lateral sclerosis; CNS disorders
Most Recent Events
- 04 Mar 2025 Passage Bio plans to seek regulatory feedback on pivotal trial design for Frontotemporal Dementia in 1H 2026
- 13 Nov 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (Intracisternal)
- 24 Oct 2024 Pharmacodynamics data from a preclinical study in Frontotemporal dementia released by Passage Bio